Apraglutide TFA
PRODUCTS SPECIFICATIONS
DESCRIPTION
Overview
| MDL | - |
|---|---|
| Molecular Weight | 3879.27 |
| Molecular Formula | C172H263N43O52.C2HF3O2 |
| SMILES | - |
Summary
Apraglutide TFA (FE 203799 TFA), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum [1] .
In Vivo
Apraglutide (FE 203799; 5 mg/kg/dose, subcutaneously, twice on days 0 and 4 postsurgery) treated piglets are healthy, have significant lower fecal fat and energy losses and exhibite intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth on day 7
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | NewbornDuroc piglets, 2-5 days old and weighing between 2-2.6 kg [1] . |
| Dosage: | 5 mg/kg/dose. |
| Administration: | Subcutaneously, twice on days 0 and 4 postsurgery. |
| Result: | On day 7, treated piglets were healthy, had significant lower fecal fat and energy losses and exhibited intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04964986 | VectivBio AG |
Short Bowel Syndrome
|
June 14, 2021 | Phase 2 |
| NCT03408132 | GlyPharma Therapeutics|VectivBio AG |
SBS - Short Bowel Syndrome
|
May 2, 2018 | Phase 1|Phase 2 |
| NCT04699032 | VectivBio AG |
Chronic Kidney Disease
|
November 30, 2020 | Phase 1 |
| NCT04627025 | VectivBio AG |
Short Bowel Syndrome
|
January 26, 2021 | Phase 3 |
| NCT05415410 | VectivBio AG |
GVHD
|
May 25, 2022 | Phase 2 |
| NCT03417765 | GlyPharma Therapeutics|VectivBio AG |
Lymphoma, Non-Hodgkin´s, Adult|Lymphoma, Hodgkin´s, Adult
|
September 1, 2018 | Phase 1|Phase 2 |
| NCT03415594 | GlyPharma Therapeutics|VectivBio AG |
Short Bowel Syndrome
|
May 8, 2018 | Phase 1|Phase 2 |
| NCT05018286 | VectivBio AG |
Short Bowel Syndrome
|
July 13, 2021 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Sealed storage, away from moisture
| Powder | -80°C | 2 years |
|---|---|---|
| -20°C | 1 year |
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O
Peptide Solubility and Storage Guidelines:
1. Calculate the length of the peptide.
2. Calculate the overall charge of the entire peptide according to the following table:
| Contents | Assign value | |
| Acidic amino acid | Asp (D), Glu (E), and the C-terminal -COOH. | -1 |
| Basic amino acid | Arg (R), Lys (K), His (H), and the N-terminal -NH 2 | +1 |
| Neutral amino acid | Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) | 0 |
3. Recommended solution:
| Overall charge of peptide | Details |
| Negative (<0) |
1. Try to dissolve the peptide in water first.
2. If water fails, add NH 4 OH (<50 μL). 3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide. |
| Positive (>0) |
1. Try to dissolve the peptide in water first.
2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO. |
| Zero (=0) |
1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration. |